Search Results

You are looking at 41 - 50 of 110 items for :

  • "aromatase inhibitor" x
  • Refine by Access: All x
Clear All
Full access

Rachel M. Layman

for treatment of this patient population: palbociclib, ribociclib, and abemaciclib. CDK4/6 inhibitor therapy in combination with aromatase inhibitors (AIs) and the selective estrogen receptor degrader fulvestrant have demonstrated efficacy for

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

levels or activity of endogenous estrogen provide a noncytotoxic alternative systemic therapy option for treating hormone-sensitive uterine sarcomas. Hormonal agents used in uterine sarcomas include aromatase inhibitors (AIs), progestins (eg

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2019

Featured Updates to the NCCN Guidelines

Tara Sanft, Crystal S. Denlinger, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

specialists. An external proposal included a request for a section specifically addressing aromatase inhibitor (AI)–induced arthralgias based on new data and the large number of survivors affected by this syndrome. A double-blind phase III RCT, which included

Full access

Mindy E. Goldman

hormone replacement therapy tend to abruptly stop when diagnosed with endocrine-dependent cancers; and vasomotor symptoms are common with hormonal drugs such as tamoxifen or aromatase inhibitors. For Dr. Goldman, the key is to be sure that menopausal

Full access

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

. Specifically, Charlson et al assessed the rates of initiation of aromatase inhibitors (AIs) versus tamoxifen in the treatment of postmenopausal women with breast cancer between 2006 and 2007. During this study period, AI therapy was recommended as part of

Full access

Charles J. Ryan and Eric J. Small

Santen RJ PG Fisch MJ Myers CE . Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma . Cancer 2001 ; 92 : 2095 – 2101 . 32 Smith M Kaufman D George D .: Selective aromatase inhibition

Full access

Juan P. Cata and Daniel D. Kim

use of side effect controlling medications among women on aromatase inhibitors [published online October 26, 2020] . J Womens Health (Larchmt) , doi: 10.1089/jwh.2020.8493 JUAN P. CATA, MD Juan P. Cata, MD, is an Associate Professor in the

Full access

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass

breast surgery and 50% in those treated with lung surgery. 1 Arthralgias, characterized by joint pain and stiffness, occur in roughly half of women taking aromatase inhibitors as adjuvant therapy for breast cancer. 15 Pelvic pain often occurs after

Full access

Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer

of 0 to 5, with 0 being “not bothersome” and 5 being “extremely bothersome.” 8 Adjuvant endocrine trials of aromatase inhibitors compared with tamoxifen have not reported an increase in bladder symptoms. 9 , 10 The Mind-Body Study reported more

Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead

postmenopausal women with hormone receptor–positive advanced breast cancer that had progressed or recurred during treatment with a nonsteroidal aromatase inhibitor randomized patients to exemestane with or without the mTOR inhibitor everolimus. 17 The results of